The Evolution of Hormonal Therapy for Prostatic Carcinoma

Reviews in Urology

Michael K Brawer¹ 

[1] Northwest Prostate Institute, Seattle, WA

关键词: Prostate cancer;    Androgen blockage;    Diethylstilbestrol;    LHRH;    GnRH antagonists;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

It is well recognized that testosterone has a number of untoward effects on prostatic carcinoma and that castration is associated with significant tumor shrinkage and resolution of symptoms of advanced prostatic carcinoma. Approaches to hormonal therapy have evolved significantly over the last several decades. Initially castration was utilized, which provided effective reduction of testicular androgens, but with adverse psychological factors. The next approach was utilization of diethylstilbestrol, but with significant cardiovascular toxicity in higher doses. The development of the luteinizing hormone-releasing hormone agonists provided an improvement in pharmacologic castration; however, they are associated with a transient testosterone surge and the potential for exacerbation of clinical manifestations of advanced prostate carcinoma (the so-called “testosterone flare”). Recently, gonadotropin-releasing hormone (GnRH) antagonists have been investigated. Abarelix is a pure GnRH antagonist that blocks the anterior pituitary receptor, resulting in prompt and significant reduction not only of luteinizing hormone but also follicle-stimulating hormone. This results in castrate levels of testosterone while avoiding the testosterone surge.

【 授权许可】

Unknown